---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-001335"
form_type: "8-K"
ticker: "PCRX"
cik: "0001396814"
company_name: "Pacira BioSciences, Inc."
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:11:32.037389+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pacira reports preliminary 2025 revenue of $726.4M; EXPAREL sales record high with 7% volume growth

## Summary
- Total revenue $726.4M vs $701.0M in FY2024, up 3.6%.
- Q4 EXPAREL net sales $155.8M (record) vs $147.7M in Q4 2024, 7% volume growth.
- Full-year EXPAREL net sales $575.1M vs $549.0M (+4.8%); ZILRETTA flat at $116.6M.
- Repurchased 2.0M shares for $50.0M in Q4; $150M remains under current authorization.
- Preliminary unaudited; full Q4/fiscal 2025 results and guidance expected later in Q1 2026.

## SEC filing metadata
- accession: 0001628280-26-001335
- form_type: 8-K
- ticker: PCRX
- cik: 0001396814
- company_name: Pacira BioSciences, Inc.
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1396814/000162828026001335/0001628280-26-001335-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1396814/000162828026001335/pcrx-20260108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-001335
- JSON: https://secwatch.observer/filing/0001628280-26-001335.json
- Plain text: https://secwatch.observer/filing/0001628280-26-001335.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.